Axillary Management in Clinically Node-Positive (cN1) Estrogen Receptor-Positive Breast Cancer
Cancers · 11.08.2026 · 18 (16) · 2574
DOI: 10.3390/cancers18162574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.08.2026. Verfasst von Jennifer Den und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Axillary management in breast cancer continues to de-escalate, with trials showing similar outcomes between sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) in clinically node-negative patients. However, equivalence has not been demonstrated in estrogen receptor-positive (ER+), clinically node-positive (cN1) patients. We hypothesize that SLNB would not be associated with inferior outcomes compared to ALND among this population.
Methods
Using the TriNetX Network, we identified women aged ≥18 years with cN1, ER+ breast cancer who underwent axillary surgery, inclusive of both upfront surgery and neoadjuvant-treated patients. Stage IV disease was excluded. The index event was the first axillary surgery (SLNB or ALND). Propensity score matching (1:1) was performed, balancing for age, receptor status, tumor characteristics, treatment, surgical procedure, and comorbidities. Outcomes included overall survival (OS) and local recurrence (LR). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox models.
Results
A total of 1162 women were identified (SLNB 641, ALND 521). After matching, 435 patients remained in each cohort. At up to 10 years, OS was similar between groups (77% vs. 76%, HR 0.9, 95% CI 0.66–1.27). Breast recurrence occurred in 5% versus 7% (HR 0.82, 95% CI 0.47–1.42). Axillary recurrence occurred in 21% versus 24% (HR 0.9, 95% CI 0.69–1.21). None of these differences reached statistical significance.
Conclusions
In ER+, cN1 node-positive breast cancer, SLNB was not associated with worse survival or recurrence compared with ALND. These real-world findings are hypothesis-generating but support the continued investigation and refinement of axillary de-escalation guidelines for clinically node-positive disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA.
- Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
ORCID-Profile: Jennifer Den, Kamil Khanipov
Zitieren
APA
Den, J., Khanipov, K., Suzanne Klimberg, V., & Vaghjiani, R. (2026). Axillary Management in Clinically Node-Positive (cN1) Estrogen Receptor-Positive Breast Cancer. Cancers, 18(16), 2574. https://doi.org/10.3390/cancers18162574
Vancouver
Den J, Khanipov K, Suzanne Klimberg V, Vaghjiani R. Axillary Management in Clinically Node-Positive (cN1) Estrogen Receptor-Positive Breast Cancer. Cancers. 2026;18(16):2574. doi:10.3390/cancers18162574
BibTeX
@article{Den2026,
author = {Den, Jennifer and Khanipov, Kamil and Suzanne Klimberg, Vicki and Vaghjiani, Raj},
title = {Axillary Management in Clinically Node-Positive (cN1) Estrogen Receptor-Positive Breast Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {16},
pages = {2574},
doi = {10.3390/cancers18162574}
}
EUVIMED